Biocom California Newsletter

What’s Inside: Biggest Takeaways from Our Global Life Science Partnering & Investor Conference; Statement on Silicon Valley Bank; Rapport Therapeutics Launches with $100M; Ionis Pharmaceuticals Expands; and more.

What’s Inside: Announcing Our New Board Members; CIRM Elects Dr. Imbasciani as Chair; Gilead Receives $7.6M to Advance Health Equity in Breast Cancer; and more.

What’s Inside: Our Focus Areas for 2023; FDA Approvals for Ferring and Gilead; NIH Commits $4.8M for All of Us Genetic Research Program; California’s Drought is Likely to Persist Even After Heavy Rainfall; and more.

What’s Inside: Our 10 Most-Read Stories of 2022; Upside Foods Gets Safety Nod from FDA for Cell-Cultured Meat; UCSD Receives $20M Gift; Take this Year’s DE&I Survey; and more.

What’s Inside: IGD Simulation Lab with Illumina; The Latest in Sustainable Materials; Vir Presents Positive Data for HBV Therapies; Midterm Election Results; and more.

What’s Inside: Black Biotech Trailblazers Event Recap; Latest in Hematology; Salk Scientists Among Curebound Grant Winners; Take Action Against TRIPS IP Waiver; and more.

What’s Inside: Member Companies Advancing Infectious Disease Testing and Treatments; A Huge Win Against Alzheimer’s; Hundreds of Bills Pending Governor’s Signature; and more.

What’s Inside: Member Companies Advancing Infectious Disease Testing and Treatments; A Huge Win Against Alzheimer’s; Hundreds of Bills Pending Governor’s Signature; and more.

What’s Inside: Latest News in Maternal and Reproductive Health; TRACON Receives Fast Track Designation for Envafolimab; Dr. Renee Wegrzyn to Lead ARPA-H; and more.

What’s Inside: FDA Authorizes Updated COVID-19 Vaccines; Biocom California Welcomes New Board of Governors Members; Latest News in Bioprinting; and more.